---

AstraZeneca has announced that its brand of capivasertib (Truqap) has demonstrated substantial efficacy in the treatment of metastatic hormone-sensitive prostate cancer.

Capivasertib is an orally bioavailable adenosine triphosphate inhibitor of all three AKT isoforms (1, 2, and 3) approved in the US, European Union, Japan, and other countries for the treatment of HR-positive (or ER-positive), HER2-negative, locally advanced or metastatic breast cancer.

Now a global clinical trial is exploring its use in prostate cancer.

The phase III study named CAPItello-281 found that among patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, capivasertib in combination with androgen deprivation therapy (ADT) and abiraterone showed a statistically significant and clinically meaningful improvement in radiographic progression-free survival.

This was in comparison to a combination of abiraterone, ADT, and placebo.

---

READ ALSO: FDA accepts for review GSK’s new multiple myeloma therapy

---

“These results show for the first time that adding an AKT inhibitor to a standard-of-care therapy can provide benefit to patients with a biomarker of PTEN-deficient metastatic hormone-sensitive prostate cancer. By targeting a key driver of the disease, we have been able to improve upon current therapies and demonstrate the potential role of this combination in an area of critical unmet need. It will be important to see greater maturity in key secondary endpoints, including overall survival,” stated Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca.

Prostate cancer is the fifth most common cause of cancer-related deaths in males worldwide and the second most common cancer in men, with an incidence of more than 1.4 million and approximately 397,000 deaths in 2022.

In patients diagnosed with metastatic prostate cancer, just one in three survive for five years.

Additionally, of the 200,000 patients who receive a metastatic hormone-sensitive prostate cancer diagnosis annually, one in four have tumors that lack PTEN, in which the prognosis is even worse.

AstraZeneca expects to present the trial’s data in an upcoming medical meeting as well as share the same with global regulatory authorities.

---

Did you find this informative? Subscribe for more.

---